Implications of capecitabine (Xeloda®) for cancer nursing practice

This publication has 21 references indexed in Scilit:

• Implementation of capecitabine (Xeloda®) into a cancer centre: UK experience
  European Journal of Oncology Nursing, 2004
• The vital role of education and information in patients receiving capecitabine (Xeloda®)
  European Journal of Oncology Nursing, 2004
• Pharmacology of Oral Chemotherapy Agents
  Clinical Journal of Oncology Nursing, 2003
• The role of nurse-led care in cancer management
  The Lancet Oncology, 2003
• 271 Savings in staff time as a result of switching from De Gramont to oral capecitabine for patients with advance colorectal cancer
  European Journal of Cancer Supplements, 2003
• Second Generation Taxanes: from the Natural Framework to the Challenge of Drug Resistance
  Current Medicinal Chemistry - Anti-Cancer Agents, 2003
• First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin
  Annals of Oncology, 2002
• Answering Patients' Needs: Oral Alternatives to Intravenous Therapy
  The Oncologist, 2001
• Waiting times for patients with cancer
  BMJ, 2000
• Information and Participation Preferences Among Cancer Patients
  Annals of Internal Medicine, 1980